Table 4.
Longitudinal outcome measures described by trial group
| T0 Baseline |
T1 Week 2 |
T2 Week 3 |
T3 + 10 days |
T4 + 3 weeks |
T5 + 6 months |
||
|---|---|---|---|---|---|---|---|
| Measure |
Mean (SD) 95% confidence interval Median (IQR) |
||||||
| FACIT-F | |||||||
| Intervention |
19.3 (8.8) 15.1–23.6 20 (9) |
20.0 (11.5) 14.8–25.6 18 (17) |
18.6 (9.9) 13.8–23.3 18 (14) |
18.8 (9.9) 14–23.6 18 (16) |
17.8 (10.5) 12.8–22.9 18 (17) |
17.1 (9.4) 10.4–23.8 17 (17) |
|
| Control |
19.6 (10.2) 12.3–26.9 19 (15) |
19.8 (9.1) 13.2–25.5 23 (17) |
21.0 (9.7) 14.4–27.5 25 (16) |
21.7 (10.7) 14.6–27.1 25 (25) |
19.3 (10.2) 12.4–26.1 26 (15) |
9.1 (9.0) 1.6–16.7 6 (18) |
|
| QLQ30 | |||||||
| Intervention |
8.6 (2.0) 7.6–9.6 8 (3) |
8.8 (2.5) 7.6–9.9 8 (2) |
8.8 (2.8) 7.5–10.1 8 (3) |
8.5 (2.6) 6.7–10.4 8 (3) |
|||
| Control |
9.8 (4.2) 7.1–12.4 9 (7) |
8.3 (2.7) 6.5–10.1 8 (4) |
9.2 (3.5) 6.8–11.6 8 (5) |
7.3 (2.8) 4.9–9.6 6 (7) |
|||
| AH self-efficacy | |||||||
| Intervention |
34.8 (12.9) 28.6–41.1 35 (17) |
40.8 (10.2) 35.9–45.7 41 (18) |
42.2 (10.7) 37.1–47.3 46 (19) |
||||
| Control |
34.7 (7.3) 30.1–39.2 34 (11) |
38.8 (14.4) 29.1–48.5 39 (20) |
35.3(17.5) 23.5–47.1 30 (22) |
||||
| HADS anxiety | |||||||
| Intervention |
7.7 (4.2) 5.7–9.7 8 (4) |
6.6 (4.0) 4.6–8.5 6 (4) |
5 (3.9) 2.2–7.8 4 (8) |
||||
| Control |
7.9 (3.1) 6.0–9.9 8 (6) |
8.5 (4.1) 5.7–11.2 9 (6) |
5.3 (4.7) 1.3–9.2 4.5 (6) |
||||
| HADS depression | |||||||
| Intervention |
5.8 (3.5) 4.2–7.5 6 (5) |
5.6 (3.7) 3.9–7.4 5 (5) |
5.6 (3.7) 3–8.2 5 (4) |
||||
| Control |
5.6 (3.7) 3.3–7.9 6 (6) |
6.7 (3.7) 4.2–9.2 7 (8) |
3.9 (2.1) 2.1–5.6 3.5 (3) |
||||